Drug Week articles from May 2003

Drug Week archives from May 2003

Drug slows progression of moderate-to-severe disease.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- A drug that quashes the activity of a key brain chemical is the first effective treatment for patients in the later stages of Alzheimer disease, according to the results of a large multicenter clinical...

Cholesterol drug prevents growth of cells in lab.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Statin drugs used to lower cholesterol may also help prevent development of breast cancer, say researchers who studied the drugs in laboratory cell cultures. The investigators, from the University...

Alliance identifies new class of agents with potential to treat HIV/AIDS.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- In a successful partnership between industry and academia, researchers from The University of Maryland, Baltimore County (UMBC) and Achillion Pharmaceuticals announced the discovery of a new target on...

Factors predicting imatinib response identified.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Factors predicting the response to imatinib have been identified. According to recent research from the United States, "imatinib induces remissions in approximately 30% of patients with chronic...

Experimental anticancer agent phenoxodiol induces death of chemoresistant cells.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Laboratory-based data confirm that phenoxodiol causes chemoresistant ovarian cancer cells to die. Researchers at Yale School of Medicine who conducted the study also found two signaling pathways that...

Company reports results from interim assessment of Reolysin trial.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Oncolytics Biotech, Inc., (ONCY) reports that Dr. Don Morris of the Alberta cancer board and the University of Calgary presented results from an interim assessment of the first six completed patients of...

Subcutaneous vitamin K alternative for patients without active bleeding.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Subcutaneously administered vitamin K is an alternative for patients with over-anticoagulation with no active bleeding. "Over-anticoagulation from warfarin is a common occurrence, and these...

Recombinant adeno-associated virus (rAAV)-based HIV vaccine shows promise.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Targeted Genetics Corp. (TGEN) announced promising data from its AIDS vaccine preclinical program at the annual Keystone AIDS Vaccine Conference, held in Banff, Alberta. In studies presented at the...

Mechlorethamine restores follicular action by targeting infiltrated lymphocytes.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Mechlorethamine restores follicular activity by targeting infiltrated lymphocytes in alopecia-areata-affected mice. "Alopecia areata is an autoimmune disease targeted at hair follicles with...

Improvement in cognition reported in patients treated with memantine, donepezil.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Forest Laboratories, Inc., (FRX) announced that researchers have presented results from the first U.S. clinical trial evaluating a combination therapy for moderate-to-severe Alzheimer disease at the...

Aranesp maintains hemoglobin levels in kidney disease patients.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Amgen (AMGN) announced preliminary results from a study evaluating the use of Aranesp (darbepoetin alfa) administered once per month to maintain target hemoglobin levels (10-12 g/dL) in chronic kidney...

Angina patients with diabetes show increase in exercise duration with Ranolazine.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- CV Therapeutics, Inc., (CVTX) announced that angina patients with diabetes who participated in the CARISA (Combination Assessment of Ranolazine in Stable Angina) trial showed a similar increase in...

Heteropolymer data presented at international anthrax meeting.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Elusys Therapeutics, Inc., presented data on its anthrax drug for the first time at the 5th International Conference on Anthrax in Nice, France. "The data show that our anthrax drug works in animals...

Education through periodic newsletter on persistence may have good effect.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Education through a periodic newsletter on persistence with antihypertensive therapy may have a positive effect. According to recent research from Japan, "Sufficient persistence with therapy is...

Clinical benefits, increased health care costs from new agents remain to be seen.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Clinical benefits vs increased health care costs from new antithrombotic agents remain to be seen. "Antithrombotic therapy in the management of an acute coronary syndrome is designed to inhibit...

Arming patients with information does change behavior.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- A new study shows that high coronary artery calcium scores are directly related to significant vessel narrowing, and asymptomatic people with high scores will make significant lifestyle changes to...

Clopidogrel studied in one of the largest trial programs.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Among the ongoing efforts against atherothrombotic disease, a major cause of the most common diseases causing death worldwide (cardiovascular and cerebrovascular disease), the antiplatelet agent...

McMaster University leads trial in the prevention of vascular events.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Patient enrollment will soon begin in the ACTIVE trial (atrial fibrillation clopidogrel trial with irbesartan for the prevention of vascular events), the largest randomized trial program ever conducted...

Oral anticoagulant studied as alternative to warfarin for stroke prevention.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Results of the largest stroke prevention trial ever conducted comparing AstraZeneca's investigational oral anticoagulant Exanta (ximelagatran) to warfarin in patients with nonvalvular atrial...

Company initiates phase I combination trial of Triapine in leukemia.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Vion Pharmaceuticals, Inc., (VION) announced that it has initiated a new phase I trial of Triapine in combination with cytarabine (Ara-C) in patients with advanced leukemia. Enrollment of patients...

Novel antiangiogenic drug appears suitable for long-term use.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Neovastat (AE-941; AEterna), an antiangiogenic drug isolated from marine cartilage, appears suitable for long-term use, report cancer researchers in Canada. Neovastat "interferes with several steps...

Rigel receives second milestone payment for cancer drug.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Rigel Pharmaceuticals, Inc., (RIGL) announced that it has received a second milestone payment from Daiichi Pharmaceuticals Co., Ltd., in conjunction with the companies' partnership to develop a new type...

Preclinical results on texaphyrin therapy presented at ACC meeting.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Pharmacyclics, Inc., (PCYC), announced that preclinical studies involving treatment with the company's texaphyrins, motexafin lutetium (Antrin Injection) and motexafin gadolinium, demonstrate the...

Obstetric product licensed out for marketing.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Cytokine PharmaSciences, Inc., (CPSI) has signed an exclusive license with Integrity Pharmaceutical Corporation for U.S. rights to market CPSI's second-generation cervical ripening product. ...

Additional safety data presented for Niaspan and Advicor.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- At the annual scientific session of the American College of Cardiology (ACC), key results from several studies were presented further supporting the safety and efficacy of Kos Pharmaceuticals, Inc's,...

Study: Nipent, in combination with cyclophosphamide, is active in CLL patients.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- SuperGen, Inc., (SUPG) announced that data from a published clinical study suggest that its anticancer compound Nipent (pentostatin for injection), in combination with cyclophosphamide, is an active...

Alliance to use skills in molecular design, chemistry synthesis.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- De Novo Pharmaceuticals (De Novo) and Peakdale Molecular (Peakdale) announced that they have entered into a joint collaboration to exploit their respective skills in molecular design and chemistry...

Oral angiogenesis inhibitor enters phase III trials.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Schering, AG, (SHR) announced that its experimental agent PTK787/ZK 222584, which is being developed in collaboration with Novartis, AG, (NVS) has entered phase III clinical trials in metastatic...

Manufacture of Actiq transferred to Salt Lake City facility.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Cephalon, Inc., (CEPH) announced that manufacture of Actiq (oral transmucosal fentanyl citrate) [C-II] for the U.S. market has been transferred from a contract manufacturer to Cephalon's recently...

Follow-up data releases from Taxus II clinical trial.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Boston Scientific Corporation (BSX) announced 12-month follow-up data from its Taxus II clinical trial. The results supported safety, as demonstrated by rates of Major Adverse Cardiac Events...

Stem cell factor ameliorates liver damage in mice.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Stem cell factor ameliorates liver damage in mice. "Acute liver injury is a common cause of intensive care unit visits," according to recent research published in the journal Laboratory...

Dermatology company begins final phase III trial for Zimycan.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Barrier Therapeutics, Inc., announced today that it has begun enrolling patients in its final phase III clinical trial for its lead product, Zimycan, a topical ointment containing 0.25% of the...

PPAR alpha/gamma activation enhances insulin sensitivity and glycemic control.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Dual PPAR alpha/gamma activation enhanced insulin sensitivity and glycemic control in ZDF rats. According to a study from Denmark and Australia, "Improvement of insulin sensitivity and lipid and...

SICOR enters copromotion alliance for Calcitriol.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- aaiPharma, Inc., (AAII) and SICOR, Inc., (SCRI) announced that they have entered into a manufacturing and copromotion agreement for Calcitriol Injection vial, a drug used primarily to treat chronic...

AHA urges ban of ephedra-based supplements.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Over-the-counter dietary supplements containing ephedra do more harm than good and should be removed from the market, according to the American Heart Association (AHA). In comments submitted to the...

BioTransplant company reports on corporate developments.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- BioTransplant, Inc., (BTRNQ.OB) reported several developments that are expected to help position the company to execute on its strategic objective of maximizing the value of its key assets through...

PEGylated drug conjugates provide effective drug delivery.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- PEGylated drug conjugates provide effective drug delivery. According to a study from the United States, "The current review presents an update of drug delivery using poly(ethylene glycol) (PEG),...

Poorly water-soluble compounds formulated as nanocrystalline particles.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Elan Drug Delivery, Pennsylvania, USA, has developed a way to formulate poorly water-soluble compounds as nanocrystalline particles. "Poorly water-soluble compounds are difficult to develop as drug...

Scientists harnessing microbes to kill tumors.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- An ingenious new way to attack cancer tumors is being developed by medical researchers from Nottingham as part of an E.U. consortium, according to work presented at the Society for General...

Antimicrobial peptides that exist in nature have large therapeutic potential.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- A review of what is known about an array of natural antimicrobial peptides also covers aspects of drug development and production. "Antimicrobial peptides (AMPs) are effector molecules of the...

Clinical research association doubles membership in first year.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Amid increasing awareness of the need for clinical research organizations to participate in health policy debates regarding drug development issues, the Association of Clinical Research Organizations...

Predictive metabolism and toxicity modeling will be increasingly possible.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Computer modeling will begin to take a greater role in determination of drug metabolism and toxicity. "In this article, we discuss recent advances and selected publication in the area of...

Two novel clostridial bacteriocins identified and characterized.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- University of Groningen biotechnologists have identified and characterized two novel clostridial bacteriocins. R. Kemperman and colleagues purified, N-terminally sequenced, and characterized "two...

Positive results released for oral insulin study.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- BioSante Pharmaceuticals, Inc., (BISP) announced that positive results of preclinical testing of its calcium phosphate (CAP) delivery system for the oral delivery of insulin were presented at the...

Blood poisoning vaccine ready for human trials.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- A combined British and U.S. research team has developed the world's first vaccine against endotoxin, which is a key cause of blood poisoning and death after major surgery for cancer or heart disease....

Data analysis shows Keppra reduced partial seizures in elderly patients.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Results of an analysis of elderly patients with epilepsy confirmed the efficacy and safety of Keppra (levetiracetam) in a real-world, community setting. The analysis, presented today at the 55th...

$3.7M in new business awards announced by healthcare company.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Covalent Group, Inc., (CVGR) announced the awarding of multiple new business contracts with an aggregate value of $3.7 million. The contracts represent a mix of new studies and expansion of current...

2003 Outlook revised by biotech company.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Cambrex Corporation (CBM) announced that its full year 2003 earnings forecast is being reduced from previous guidance and that the company has decided to enter into a settlement and indemnity agreement...

Annual sales revenue increases for biotech company.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Cell Robotics International, Inc., (CRII) announced financial results for the fourth quarter and year ended December 31, 2002. The company reported increases in revenues from product sales for both...

Board authorizes common stock repurchase program; reports financial results.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- BioDelivery Sciences International, Inc., (BDSI; BDSIW) announced that the company's board of directors has authorized the repurchase of up to 100,000 shares of the company's common stock. Under...

Commitment for $10M equity secured.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Deltagen, Inc., (DGEN) announced that it has secured a minimum commitment for $10 million in equity capital from existing institutional investors to purchase preferred stock in a private placement. ...

First quarter guidance updated by genomics company.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Affymetrix, Inc., (AFFX), reported that based on preliminary financial data, the company expects product and related revenue as well as net income for the first quarter of 2003 to be lower than previous...

MS drug maker announces improved performance expectations.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Biogen, Inc., (BGEN) announced revised guidance for first quarter 2003 earnings per share, which are now expected to be in the range of $0.39-$0.43. Included in this estimate are $0.08 per share of...

Pharmaceutical company reports net loss of $0.03 per share.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Cadus Pharmaceutical Corporation (KDUS.OB) announced financial results for the fourth quarter and full year ended December 31, 2002. Revenues for the fourth quarter of 2002 were $1,000,000, compared...

Proteomics company reports a 2.4% increase in revenue.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Boston Biomedica, Inc., (BBII) announced that revenue from continuing operations for the fourth quarter ended December 31, 2002, was $6,079,454, an increase of $144,151 or 2.4%, compared with revenue...

Revenue forecast lowered at biotech company.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Array BioPharma, Inc., (ARRY) announced that it is lowering its revenue forecast due to general market softness and the ending of two significant drug discovery collaborations. Overall, Array...

Revenue, earnings guidance lowered for first quarter 2003.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Cerner Corporation (CERN) announced that it expects its first quarter 2003 revenue and earnings to be below expectations because of a lower level of new business bookings in the quarter. The...

Systems biology company announces issuance of key patent.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Clinomics Biosciences, Inc., announced the issuance of a United States patent (Patent Number 6,534,307) that enables the design and production, for the first time, of Frozen Tissue Microarrays. "We...

FDA approves generic Methocarbamol tablets.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Lannett Co., Inc., (LCI), a manufacturer of generic pharmaceuticals, announced it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market Methocarbamol tablets,...

FDA approves Valtrex caplets for recurrent infections in HIV patients.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- The U.S. Food and Drug Administration (FDA) has approved GlaxoSmithKline's supplemental new drug application (sNDA) for Valtrex (valacyclovir HCl) caplets for the suppression of recurrent genital herpes...

IND filed for anti-HIV drug candidate AMD-070, a CXCR4 HIV entry inhibitor.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- AnorMED, Inc., (AOM) announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) for approval to begin its clinical program for AMD-070, a...

Novel assay useful for evaluating neuroprotective agents.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- A novel assay can help determine the efficacy of neuroprotective agents for patients with advanced HIV disease. HIV-associated central nervous system disorders, "including encephalopathy, often...

Scytonema varium bacteria yield potent antiviral agent.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Cultured cyanobacteria have yielded a powerful antiviral agent. In a recent study from the United States, "a new anti-HIV protein, scytovirin, was isolated from aqueous extracts of the cultured...

Vatica cinerea extracts show antiretroviral activity.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Extracts from a Vietnamese medicinal plant have demonstrated potent antiretroviral activity. "In a continuing search for anti-HIV compounds from the plants of Vietnam, 19 compounds, including a new...

Anti-Vpu antibodies are sign of effective treatment.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- The emergence of antibodies targeting the HIV Vpu protein is a sign of effective antiretroviral treatment. HIV Vpu "promotes both extracellular release of viral particles and degradation of CD4 in...

Low nelfinavir plasma levels linked to treatment failure.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Low levels of nelfinavir in plasma may underlie treatment failure in HIV patients. "Virological failure to protease inhibitor (PI)-based antiretroviral regimens is often not explained by the...

Novel electrophoretic assay can measure all 15 antiretroviral agents.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- A capillary electrophoresis-based assay can measure levels of all 15 antiretroviral agents used for HIV treatment. Researchers in Austria described "a novel approach towards a complete separation...

Treatment interruptions reduce quality-of-life.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Interruptions in HIV treatment reduce patients' quality of life. Researchers in Canada conducted a study "to examine health-related quality of life (HRQOL) before, during and after treatment...

Trichosanthin ribosome suppression not linked to antiretroviral effects.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- The antiretroviral effects of trichosanthin (TCS) are not linked to its effects on ribosomes. TCS "is a type I ribosome-inactivating (RI) protein possessing multiple biological and pharmacological...

Effects on cardiovascular parameters measured during studies are examined.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Effects changing HR, alone, on cardiovascular parameters measured during pharmacological and toxicological studies are evaluated. "Cardiovascular parameters were measured in dogs after RR interval...

KV Pharmaceutical Co. acquires Niferex product line and two product lines from ALTANA.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- KV Pharmaceutical Co. (KVa/KVb) announced that it has concluded an agreement with Schwarz Pharma to acquire the Niferex product line for its Ther-Rx Corp. branded marketing division. The Niferex...

FDA approves Pamine Forte.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Bradley Pharmaceuticals, Inc., (BPRX) has received a supplemental New Drug Application approval for prescription-only Pamine Forte (methscopolamine bromide), a 5 mg, lactose-free tablet that represents...

FK506 blocks IL2 synthesis, FAP48-FKBP complexes increase IL2 production.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- FK506 blocks IL2 synthesis and FAP48-FKBP complexes increase IL2 production. "FAP48 was identified and cloned thanks to its interaction with FK506-binding proteins (FKBPs) such as FKBP52 and FKBP12,...

Novel assay enables quantification of ofloxacin isomers.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- A novel assay enables the quantification of ofloxacin isomers in serum. "Ofloxacin, a chiral fluoroquinolone, possesses two optical isomers. The antibacterial activity of S-(-)-ofloxacin is reported...

Thomas Jefferson University to jointly develop applications for IBD.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Pyrosequencing, AB, (PYRO) and Thomas Jefferson University, Philadelphia, announced that they have entered into a sponsored research agreement to analyze genes and develop applications for inflammatory...

NDA filed for Estorra.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Sepracor, Inc., (SEPR) announced that the U.S. Food and Drug Administration (FDA) has filed Sepracor's New Drug Application (NDA) for Estorra brand eszopiclone 2 mg and 3 mg tablets for the treatment of...

Suit alleges investors misled about application for generic Wellbutrin.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- On April 1, 2003, the law firm of Berger & Montague, P.C. filed a class action suit against Andrx Corporation and certain of its principal officers in the United States District Court for the Southern...

Obesity therapy with leptin disappointing.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Obesity therapy with leptin has been disappointing, leading to the conclusion that leptin must be modified to improve its therapeutic potential. According to recent research published in the journal...

Hemodialysis or hemofiltration to remove drug should be performed if available.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Hemodialysis or hemofiltration to remove lisinopril from bloodstream in pregnancy should be performed if available. "In general, angiotensin converting enzyme (ACE) inhibitors should be...

Expanded phase II trial of GVAX vaccine launched.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Cell Genesys, Inc., (CEGE) announced that enrollment has been opened for a multicenter phase II clinical trial of GVAX lung cancer vaccine in patients with advanced-stage, non small-cell lung cancer...

GL331 blocks tumor angiogenesis possibly by inhibiting HIF-1 alpha expression.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- The epipodophyllotoxin derivative, GL331 (Genelabs Inc.), blocks tumor angiogenesis possibly by inhibiting hypoxia-inducible factor 1 alpha (HIF-1 alpha) expression, one study suggests. To try to...

New chemotherapy regimens improve response to malignant pleural mesothelioma.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Malignant pleural mesothelioma treatments are improving in response rates, although none to date are satisfactory. According to a study from Austria, "This review summarizes the results of...

Azidothymidine highly effective in combination with interferon-alpha.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Azidothymidine combined with interferon-alpha is highly effective against HIV- and AIDS-related lymphoma. "The survival of viral mediated lymphomas depends upon constitutive nuclear factor kappa B...

Artemisinin-derived trioxane dimers show improved efficacy, oral activity.
May 2, 2003... 2003 MAY 2 - (NewsRx.com & NewsRx.net) -- Novel antimalarial agents derived from artemisinin are much more potent and orally active than their parent, and show anticancer activity to boot. In a recent study from the United States, "in only...